Strategic Pricing & Market Access,Health Economics & Outcomes Research

consulting in life sciences

Do you want your research investment to produce great returns?O

ur c

ompa

ny

Market Access is a passage obligéto commercial success. Not integratingmarket access early in developmentcan seriously jeopardize your returnon investment.

Creative answers to your challenges

Creativ-Ceutical is an international consulting firm dedicated to supporting the life science industry and health authorities in strategic decision making. We provide pricing, market access, health economics and outcomes research services that combine strong technicalknow-how with real strategic expertise.

We have broad experience in the areas of central nervous system, oncology, vaccines and rare diseases. These are complex and developing fields, where treatment paradigmsare in constant evolution and where clinicaland economic issues require rigorous analysis to determine the best choices. With thisunderstanding, we can anticipate issues that will arise in other therapeutic domains, and address even the most difficult challenges.

The youth and size of our company gives us flexibility and encourage innovative thinking,while our collective experience gives us the maturity and perspective to anticipate and address the real needs of our customers.

Mondher Toumi, MD - PhD Founder & President

”

“

�Multidisciplinary skills drawn from industry, academia and agencies

�Strong understanding of the European healthcare environment,with direct access to top-level experts and decision-makers

�Growing local presence for deep country insight. Offices in Luxembourg, France, UK, Denmark, Tunisia.

Key Strengths to Serve Your Needs

�40 employees with top qualif ications in statist ics,health economics, public health, medicine, econometrics

�Published experts, with leading-edge methodology knowledge

�A wealth of experience, gained at major pharmaceutical companies and prestigious European institutions

A Dedicated and Passionate Team

Market Access Value Chain©

Our

ser

vice

s

Market access, the “fourth hurdle” in drug development, is an inescapable reality for pharmaceutical, medical device and biotechcompanies. No company can expect to succeedwithout designing a pricing and reimbursementstrategy early in the development process.

To maximize the value of your product, rely onour insight and advice from planning to execution. We work closely with clients to definea clear path to achieve the best market accessconditions, and then deliver the strategic andtechnical services to:

� Perform pricing research among payersand stakeholders, including conjoint and discrete-choice analysis.

� Prepare and manage payer discussions atnational and regional levels.

Early-stage product profiling from a payer perspective is a key step towards value creation. It is not enough to show that your product works;payers want to know how well, relative to what alternative and all this needs projecting 3-5 yearsinto the future in a dynamic marketplace.

Pricing, Reimbursement & Market Access Strategy

Adam Plich, MScPMA Director Associate

Our Market Access Value Chain© identifies the key levers to optimize pricing, reimbursement and access conditions for your product, andorganizes activities into a coherent, integrated plan.

”

“

� Define market entry strategies to optimise reference pricing.

� Build the value story for the core value dossier and prepare for HTA.

How can your new product successfully access the market?

Our

ser

vice

s

Health Economics & Outcomes Research

Health economics addresses issues related to scarcity in the allocation healthcare resources.With limited means, payers must make hardchoices among multiple, different interventions to make the best use of available funding. In thiscontext, proving value for money is crucial, but the challenges are many. What is the appro-priate comparator? Across what time-frame?From which perspective? These are just a few of the questions we help our clients to address.

Outcomes research studies the end results ofhealthcare interventions. With payers lookingbeyond efficacy to real-world effectiveness, demonstrating end results is of increasingimportance to our clients.

To demonstrate to payers that your drug or device improves clinical outcomes enough to justify funding, we align our technical serviceswith your strategic needs to ensure that results areof value to your business.

Samuel Aballéa, MScHealth Economics & Outcomes Research Director

How to best determinethe value of your drugor device in the real world?

It is vital to go beyond discussions of technique, toconsider the true consequences of our research onour clients, on patients and on society in general.Our work definitely has a social dimension.”

“

Our experts can help you to define and execute health economic and outcomes research projects in the following areas:

�Modelling of cost-effectiveness and budgetary impact analysis

�Piggyback analysis alongside clinical trials

�Patient database analyses, e.g. real-life efficacy, compliance, safety

�Preference elicitation studies

�Patient-reported outcome studies

�Epidemiological studies

�Burden of illness studies

� Literature reviews

Our HEOR solutions

Our

ser

vice

s

Creativ-Ceutical has created a proprietary portfolio management tool box to address this challenge using the most suitable analytic approaches for the decision at hand. We helpour clients identify the right choices at the righttime during the development cycle of a drug.

Our portfolio tool enables clients to compute arisk-revenue curve based on a detailed productattribute analysis. Any project can be analysed

separately based on this multidimensional approach and put in the context of the overallportfolio and the company strategy. Theseinstruments are based on a Bayesian stochasticmethodology and multi-trait analysis.

Creativ-Ceutical also provides advisory supportin the development of licensing strategies, andcan act as a facilitator or as an assessor duringdue diligence for acquisitions or divestitures.

Portfolio Management & Licensing

Business Intelligence & Market Research

A product launch plan requires relevant and precise information that feeds each strategic decision. In today's complex life sciences markets,development decisions require more than simplyfacts and data. Projections using probabilistictechniques, simulations, scenario planning andtrade-off analysis are all approaches that can improve decision-making. But how to select themost appropriate methods and develop real insight that can effectively guide your choices?

Creativ-Ceutical is experienced with these andother approaches, and can provide expert guidance for your development and launchplans. Our methods apply to:

� Forecasting and modelling

� Market value driver identification

� Positioning and messaging research

� Segmentation studies

How to select the most appropriatemethods and develop real insightthat can effectively guide your decisions?

©2011 C

reat

iv-C

eutica

l S.A

. All

Rig

hts

Res

erve

d.

Luxembourg33, boulevard du Prince Henri

1724 Luxembourg

France215, rue du Faubourg Saint-Honoré

75008 Paris

United Kingdom29/30 Windmill Street

London W1T 2JL

TunisiaRue du lac HuronRésidence Farah

1053 Les Berges Du Lac

DenmarkFruebjergvej 3

2100 København Ø